Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $854

Benzinga Newsdesk www.benzinga.com Negative 86.1%

Neg 86.1% Neu 0% Pos 0%

Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $855 to $854.